# Expert committees and study groups 

# Membership of expert advisory panels and meetings of expert committees 

Report by the Secretariat ${ }^{1}$

## ESTABLISHMENT OR DISESTABLISHMENT OF EXPERT ADVISORY PANELS

1. No change has occurred during 2005.

## MEMBERSHIP OF THE EXPERT ADVISORY PANELS

2. Membership of the 52 expert advisory panels totalled 793 in December 2005, compared with 880 in December 2004. Of the regional distribution of all members of all panels, $8 \%$ come from the African Region, 24\% from the Region of the Americas, 10\% from the South-East Asia Region, 36\% from the European Region, 9\% from the Eastern Mediterranean Region and 13\% from the Western Pacific Region. Of the total of all members of all panels, $22 \%$ are women.
3. Attached is a list of all panels, which includes a breakdown of members by panel, region and sex, as of December 2005. Further details (namely, an alphabetical list of experts giving nationality) can be made available should members of the Board so request.

## MEETINGS OF EXPERT COMMITTEES

4. The following committees met in 2005:

Advisory Committee on Health Research (44th Session), Geneva, 25-27 April (12 members: nine men, three women); (45th Session), Geneva, 7-9 November (14 members: 10 men, four women)

[^0]Joint FAO/WHO Expert Committee on Food Additives (64th Session), Rome, 8-17 February (seven WHO members: six men, one woman); (65th Session), Geneva, 7-16 June (five WHO members: four men, one woman)

Expert Committee on Biological Standardization, Geneva, 24-28 October (10 members: nine men, one woman)

Expert Committee on Specifications for Pharmaceutical Preparations, Geneva, 24-28 October (nine members: six men, three women)

Expert Committee on the Selection and Use of Essential Medicines, Geneva, 7-11 March (11 members: five men, six women)
5. Invitations to take part in these meetings were extended to 68 panel members from 30 different countries, drawn from nine expert advisory panels (eight members were unable to attend).

# MEMBERSHIP OF WHO EXPERT ADVISORY PANELS BY PANEL AND REGION 

Numbers of panel members, as of December 2005

| WHO expert advisory panels | Africa |  | The Americas |  | South-East Asia |  | Europe |  | Eastern Mediterranean |  | Western Pacific |  | Total |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | N | W | N | W | N | W | N | W | N | W | N | W | N | W | \% |
| Acute bacterial diseases | 0 | 0 | 4 | 0 | 1 | 0 | 4 | 0 | 1 | 0 | 0 | 0 | 10 | 0 | 0 |
| Acute diarrhoeal diseases and other enteric infections | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 2 | 50 |
| Ageing and health | 2 | 2 | 4 | 3 | 1 | 0 | 9 | 2 | 2 | 1 | 0 | 0 | 18 | 8 | 44 |
| Biological standardization | 0 | 0 | 7 | 2 | 3 | 1 | 14 | 3 | 1 | 0 | 4 | 0 | 29 | 6 | 21 |
| Blood transfusion medicine | 3 | 0 | 2 | 1 | 1 | 1 | 5 | 1 | 3 | 2 | 2 | 1 | 16 | 6 | 38 |
| Brucellosis | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer | 0 | 0 | 9 | 2 | 1 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 17 | 2 | 12 |
| Cardiovascular diseases | 2 | 0 | 3 | 0 | 2 | 0 | 7 | 0 | 3 | 0 | 4 | 0 | 21 | 0 | 0 |
| Chronic degenerative diseases (diabetes) | 2 | 0 | 3 | 0 | 1 | 1 | 6 | 0 | 1 | 0 | 2 | 0 | 15 | 1 | 7 |
| Chronic degenerative diseases (rheumatic diseases) | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 33 |
| Clinical surgical procedures | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 7 | 0 | 0 |
| Development of human resources for health | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Drug dependence (dependence liability evaluation) | 0 | 0 | 6 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 4 | 1 | 13 | 2 | 15 |
| Drug dependence and alcohol problems | 0 | 0 | 3 | 2 | 1 | 0 | 7 | 2 | 1 | 0 | 4 | 1 | 16 | 5 | 31 |
| Drug evaluation | 4 | 1 | 7 | 2 | 3 | 2 | 9 | 4 | 5 | 1 | 2 | 2 | 30 | 12 | 40 |
| Drug policies and management | 3 | 2 | 2 | 0 | 4 | 2 | 8 | 5 | 1 | 0 | 5 | 2 | 23 | 11 | 48 |
| Food safety | 2 | 0 | 14 | 5 | 2 | 1 | 13 | 1 | 0 | 0 | 6 | 0 | 37 | 7 | 19 |
| Health laboratory services | 3 | 0 | 5 | 1 | 1 | 1 | 8 | 2 | 4 | 2 | 1 | 1 | 22 | 7 | 32 |
| Health promotion and education | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 100 |
| Health science and technology policy | 5 | 3 | 4 | 2 | 1 | 1 | 5 | 0 | 2 | 0 | 4 | 2 | 21 | 8 | 38 |
| Human cell, tissue and organ transplantation | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 4 | 0 | 0 |
| Human genetics | 2 | 0 | 6 | 1 | 2 | 0 | 10 | 1 | 2 | 1 | 2 | 0 | 24 | 3 | 13 |
| Human reproduction | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 1 | 33 |
| Immunology | 0 | 0 | 3 | 0 | 3 | 0 | 5 | 0 | 1 | 0 | 2 | 0 | 14 | 0 | 0 |
| Injury and violence prevention and control | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
| International pharmacopoeia and pharmaceutical preparations | 8 | 0 | 11 | 8 | 2 | 2 | 29 | 10 | 4 | 0 | 9 | 0 | 63 | 20 | 32 |
| Leprosy | 0 | 0 | 4 | 0 | 4 | 0 | 4 | 1 | 2 | 0 | 1 | 0 | 15 | 1 | 7 |
| Malaria | 1 | 0 | 2 | 0 | 3 | 0 | 11 | 0 | 2 | 0 | 0 | 0 | 19 | 0 | 0 |


| WHO expert advisory panels | Africa |  | The Americas |  | South-East Asia |  | Europe |  | Eastern Mediterranean |  | Western Pacific |  | Total |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | N | W | N | W | N | W | N | W | N | W | N | W | N | W | \% |
| Maternal and child health | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 5 | 2 | 0 | 0 | 9 | 2 | 22 |
| Mental health | 0 | 0 | 7 | 1 | 4 | 2 | 15 | 2 | 2 | 0 | 5 | 2 | 33 | 7 | 21 |
| Neurosciences | 1 | 0 | 0 | 0 | 1 | 1 | 5 | 0 | 0 | 0 | 0 | 0 | 7 | 1 | 14 |
| Nursing | 2 | 2 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 18 | 18 | 100 |
| Nutrition | 0 | 0 | 5 | 0 | 1 | 0 | 4 | 1 | 5 | 2 | 4 | 0 | 19 | 3 | 16 |
| Oral health | 2 | 0 | 1 | 0 | 3 | 1 | 9 | 1 | 2 | 0 | 2 | 0 | 19 | 2 | 11 |
| Parasitic diseases (filarial infections) | 2 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 |
| Parasitic diseases (general parasitology) | 3 | 0 | 7 | 3 | 2 | 1 | 14 | 2 | 2 | 0 | 3 | 0 | 31 | 6 | 19 |
| Parasitic diseases (leishmaniasis) | 0 | 0 | 1 | 0 | 1 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 |
| Parasitic diseases (schistosomiasis) | 2 | 0 | 7 | 0 | 0 | 0 | 8 | 0 | 3 | 1 | 7 | 0 | 27 | 1 | 4 |
| Parasitic diseases (trypanosomiases) | 1 | 0 | 10 | 5 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 18 | 5 | 28 |
| Prevention of blindness | 2 | 1 | 5 | 2 | 2 | 0 | 4 | 0 | 2 | 0 | 4 | 0 | 19 | 3 | 16 |
| Prevention of deafness and hearing impairment | 0 | 0 | 3 | 0 | 1 | 1 | 4 | 1 | 1 | 0 | 2 | 0 | 11 | 2 | 18 |
| Rabies | 1 | 0 | 3 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 8 | 0 | 0 |
| Radiation | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 4 | 0 | 0 |
| Rehabilitation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Respiratory infections | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Sexually transmitted infections, including those due to human immunodeficiency virus | 1 | 0 | 3 | 1 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 8 | 2 | 25 |
| Traditional medicine | 2 | 0 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 8 | 2 | 25 |
| Tuberculosis | 4 | 2 | 6 | 1 | 2 | 0 | 7 | 3 | 2 | 1 | 5 | 1 | 26 | 8 | 31 |
| Vector biology and control | 2 | 0 | 7 | 0 | 5 | 2 | 13 | 2 | 3 | 0 | 6 | 1 | 36 | 5 | 14 |
| Virus diseases | 1 | 0 | 4 | 0 | 3 | 1 | 5 | 0 | 0 | 0 | 1 | 0 | 14 | 1 | 7 |
| Virus diseases (antivirals and interferon) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Zoonoses | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 6 | 0 | 0 |
| Total | 64 | 13 | 189 | 48 | 79 | 26 | 288 | 49 | 73 | 17 | 100 | 19 | 793 | 172 | 22 |
|  |  | 20\% |  | 25\% |  | 33\% |  | 17\% |  | 17\% |  | 19\% |  |  |  |

N : total number of panel members; W : number of women members; \%: percentage of total number of panel members who are women.


[^0]:    ${ }^{1}$ This report is submitted to the Executive Board in compliance with Regulation 4.23 of the Regulations for Expert Advisory Panels and Committees.

